Moody's Warns of Potential Credit Impact in Middle East Amid Gaza Conflict

Smoke rises after Israeli airstrikes in Khan Yunis in the southern Gaza Strip. (Environmental Protection Agency)
Smoke rises after Israeli airstrikes in Khan Yunis in the southern Gaza Strip. (Environmental Protection Agency)
TT

Moody's Warns of Potential Credit Impact in Middle East Amid Gaza Conflict

Smoke rises after Israeli airstrikes in Khan Yunis in the southern Gaza Strip. (Environmental Protection Agency)
Smoke rises after Israeli airstrikes in Khan Yunis in the southern Gaza Strip. (Environmental Protection Agency)

Moody's Investor Services expected significant negative credit repercussions on all sovereign bodies in the Middle East if the military conflict in Gaza escalates into a multi-front confrontation.

The agency emphasized, however, that the credit impact if the conflict remains confined to Gaza, would be limited to the Middle East and North African governments (MENA).

"Geopolitical developments remain a key risk," stated Moody’s.

Moody's projects a GDP growth of 2.7% in MENA for 2024, a notable increase from the 1.1% recorded in 2023. Excluding the volatile growth associated with the oil and gas sector, the real GDP of the region is estimated to reach 3.1%, slightly down from the 3.4% observed in 2023.

The agency points out that economic activity in Saudi Arabia, UAE, Jordan, Kuwait, Morocco, Oman, and Qatar is expected to benefit from implementing state-backed mega-projects. The growth of non-oil GDP in 2024 is forecasted to outpace levels observed in 2018 and 2019, excluding Egypt and Iraq.

“Moody’s outlook for sovereign creditworthiness in MENA is stable,” it added.

However, it noted that high-interest rates and restricted capital inflows in emerging markets could impede debt sustainability and limit foreign funding for sovereign bodies. This concern is particularly pertinent in the face of economic challenges in Egypt, Lebanon, and Tunisia.



UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
TT

UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM

Mubadala Investment Company has acquired an 80% stake in Global Medical Supply Chain (GMSC) and Al Ittihad Drug Store (IDS) from GlobalOne Healthcare Holding (GHH), with GHH retaining a 20% stake, Emirates News Agency (WAM) reported on Tuesday.

This strategic acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors, aligning with the UAE's vision to establish a robust life sciences infrastructure, WAM said.

Founded in 2015, GMSC provides comprehensive end-to-end supply chain services for medical products, including demand planning, procurement, logistics, inventory management, warehousing, and maintenance.

GMSC serves over 200 medical facilities, including hospitals and clinics across the UAE. With a dedicated team of medical supply chain specialists, GMSC sources a broad array of products from almost 400 suppliers, ensuring a reliable supply chain for all medical needs.

IDS, established in 1987, stands as one of the leading distributors of pharmaceutical and consumer healthcare products in the UAE. Distributing over 1,000 products from over 40 leading suppliers, IDS services every hospital, and all, or at least most pharmacies and supermarkets within the UAE. It boasts a vast portfolio that spans multiple therapeutic categories including anti-infectives, asthma, diabetes, and oncology.

"The expanding pharmaceutical market drives an increasing demand for specialized and efficient drug logistics solutions. By integrating GMSC and IDS into our portfolio, we are poised to create a vertically integrated life sciences sector in the UAE and enable its potential to encompass the entire value chain from logistics and distribution to specialized manufacturing,” said Executive Director of UAE Clusters at Mubadala's UAE Investments Platform Ismail Ali Abdulla.

As for Low Ping, Group CEO Yas Holding, she said that the transaction “continues Mubadala's strategic growth, following another significant acquisition by its new speciality pharmaceutical business, KELIX bio, which recently acquired a 100% stake in four pharma assets from GlobalOne Healthcare Holding's, the healthcare division of Yas Holding.”

“These concerted efforts underline Mubadala's commitment to strengthening the UAE's healthcare and pharmaceutical sectors as part of broader national ambitions for drug security and economic diversification."

GlobalOne Healthcare Holding LLC serves as the dedicated Healthcare Division of Yas Holding LLC, focusing on enhancing healthcare outcomes by investing in innovative solutions across various healthcare verticals.